BioDelivery Sciences shares down on topical gel Phase III trial results

31 March 2015

BioDelivery Sciences' shares (Nasdaq: BDSI) were down up to 30% following the drugmaker’s announcement that its clonidine topical gel did not meet the primary endpoint of its Phase III trial.

The study of 140 adults was comparing clonidine to placebo in the treatment of painful diabetic neuropathy. Patients were randomized to receive either clonidine or placebo for 12 weeks, with the primary outcome set as a change in average pain score over time.

Andrew Finn, executive vice president of product development, said: "Based on the results of our previously announced positive interim analysis, this outcome was unexpected. The interim analysis data showed a difference compared to placebo of -0.94 with a standard deviation of 2.2 which was close to our study assumption of -1.0 and 1.8, respectively, and very similar to the prior Phase II study conducted by our licensor Arcion."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK